OptimizeRx Corp (OPRX) stock
OPRXNasdaqServices-Business Services, NECFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 10/3030% below fair value
$6.94+0.30 (+4.52%)
Close on Nov 17, 2026Market cap $130.72MP/E 28.9Yield –
OptimizeRx price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
OptimizeRx's price to sales ratio was 1.7× on Nov 11, 2026, against 2.6× a year earlier. Over the last 5 years it ranged from 0.9× to 19.2×, with a median of 2.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.7× | −0.4 |
| 2025 | Dec 31, 2025 | 2.1× | +1.1 |
| 2024 | Dec 31, 2024 | 1.0× | −3.2 |
| 2023 | Dec 29, 2023 | 4.2× | −0.6 |
| 2022 | Dec 30, 2022 | 4.8× | −14.4 |
| 2021 | Dec 31, 2021 | 19.2× | +0.1 |
| 2020 | Dec 31, 2020 | 19.1× | +13.1 |
| 2019 | Dec 31, 2019 | 6.0× | −1.1 |
| 2018 | Dec 31, 2018 | 7.0× | +2.6 |
| 2017 | Dec 29, 2017 | 4.4× | +1.2 |
| 2016 | Dec 30, 2016 | 3.2× | −1.7 |
| 2015 | Dec 31, 2015 | 4.9× | +0.5 |
| 2014 | Dec 31, 2014 | 4.4× | −6.7 |
| 2013 | Dec 31, 2013 | 11.1× | – |
See a number that looks wrong?